Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27688172 | 1.00 | AKR1B1 (0.42) | AKR1B1 | |
| Demannose SCHEMBL28314921 | 0.83 | LMNA (0.38) | AKR1B1 | |
| SCHEMBL14129443 | 0.81 | AKR1B1 (0.33) | AKR1B1 | |
| SCHEMBL27558595 | 0.78 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL22692164 | 0.78 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL14323419 | 0.78 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL5382389 | 0.78 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL310198 | 0.78 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL16333169 | 0.78 | AKR1B1 (0.40) | AKR1B1 | |
| SCHEMBL3749152 | 0.76 | AKR1B1 (0.39) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220489-B1 | METHOD FOR PREDICTING RE-SENSITIZATION TO STEROID THERAPY | INDEX PHARMACEUTICALS AB (SE) | 2015-02-18 | — | — | EP | disclosed |
| US-8895522-B2 | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease | INDEX PHARMACEUTICALS AB (SE) | 2014-11-25 | — | — | US | disclosed |
| US-20140030723-A1 | Method for Predicting the Response to a Therapy | INDEX PHARMACEUTICALS AB (SE) | 2014-01-30 | — | — | US | disclosed |
| EP-2269622-B1 | CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient | INDEX PHARMACEUTICALS AB (SE) | 2013-12-25 | — | — | EP | disclosed |
| US-8592390-B2 | Immunostimulatory method | INDEX PHARMACEUTICALS AB (SE) | 2013-11-26 | — | — | US | disclosed |
| US-8574834-B2 | Method for predicting the response to a therapy | INDEX PHARMACEUTICALS AB (SE) | 2013-11-05 | — | — | US | disclosed |
| US-8569257-B2 | Method for modulating responsiveness to steroids | INDEX PHARMACEUTICALS AB (SE) | 2013-10-29 | — | — | US | disclosed |
| EP-2380584-B1 | Immunostimulatory method | INDEX PHARMACEUTICALS AB (SE) | 2013-10-16 | — | — | EP | disclosed |
| EP-2179737-B1 | Modulating responsiveness to steroids | INDEX PHARMACEUTICALS AB (SE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2402442-B1 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2007055704-A2 | IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS COMPRISING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | IDERA PHARMACEUTICALS (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105800-A1 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105801-A1 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | IDERA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007050034-A1 | COMPOSITION AND METHOD FOR THE PREVENTION, TREATMENT AND/OR ALLEVIATION OF AN INFLAMMATORY DISEASE | INDEX PHARMACEUTICALS AB (SE) | 2007-05-03 | — | — | WO | disclosed |
| US-20060287261-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060211641-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2006-09-21 | — | — | US | disclosed |
| US-20060019918-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601789-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | HYBRIDON, INC. | 2004-10-07 | — | — | US | disclosed |
| WO-2004064782-A2 | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF OLIGONUCLEOTIDE-BASED COMPOUNDS BY UTILIZING MODIFIED IMMUNOSTIMULATORY DINUCLEOTIDES | HYBRIDON, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211641-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, NT5E | AKR1B1 2402/4885 |
| US-20070105801-A1 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | NT5C2, TLR9, NT5E | AKR1B1 3573/4885 |
| US-20040198685-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR5 | AKR1B1 2309/4885 |
| US-20060019918-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, NT5E | AKR1B1 2398/4885 |
| US-20060287261-A1 | Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides | NT5C2, ENTPD5, NT5E | AKR1B1 2398/4885 |
| US-20070105800-A1 | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides | NT5C2, ENTPD5, TLR9 | AKR1B1 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.